These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10445543)

  • 1. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse.
    Reinisch W; Gasché C; Tillinger W; Wyatt J; Lichtenberger C; Willheim M; Dejaco C; Waldhör T; Bakos S; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1999 Aug; 94(8):2156-64. PubMed ID: 10445543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment.
    Teml A; Kratzer V; Schneider B; Lochs H; Norman GL; Gangl A; Vogelsang H; Reinisch W
    Am J Gastroenterol; 2003 Oct; 98(10):2226-31. PubMed ID: 14572572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.
    Gelbmann CM; Rogler G; Gross V; Gierend M; Bregenzer N; Andus T; Schölmerich J
    Am J Gastroenterol; 2002 Jun; 97(6):1438-45. PubMed ID: 12094862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
    Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
    Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of Crohn's disease following corticosteroid-induced remission.
    Papi C; Festa V; Leandro G; Moretti A; Tanga M; Koch M; Capurso L
    Am J Gastroenterol; 2007 Apr; 102(4):814-9. PubMed ID: 17222316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.
    Naftali T; Novick D; Gabay G; Rubinstein M; Novis B
    Isr Med Assoc J; 2007 Jul; 9(7):504-8. PubMed ID: 17710779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
    Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
    Domènech E; Hinojosa J; Esteve-Comas M; Gomollón F; Herrera JM; Bastida G; Obrador A; Ruiz R; Saro C; Gassull MA;
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1347-52. PubMed ID: 15606397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease.
    Song L; Hanlon DW; Chang L; Provuncher GK; Kan CW; Campbell TG; Fournier DR; Ferrell EP; Rivnak AJ; Pink BA; Minnehan KA; Patel PP; Wilson DH; Till MA; Faubion WA; Duffy DC
    J Immunol Methods; 2011 Sep; 372(1-2):177-86. PubMed ID: 21821036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.
    Becker K; Niederau C; Frieling T
    Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
    Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
    Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
    Charpignon C; Beau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
    Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
    Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.